Pre-surgical oncolytic virotherapy improves breast cancer outcomes

Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullins-Dansereau, Victor, Petrazzo, Grégory, Geoffroy, Karen, Béland, Delphine, Bourgeois-Daigneault, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791421/
https://www.ncbi.nlm.nih.gov/pubmed/31646102
http://dx.doi.org/10.1080/2162402X.2019.1655363
Descripción
Sumario:Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).

Ejemplares similares